BeiGene
beigene.comTotal trials
135
Active
26
Phase 3
23
Total enrollment
22,389
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 38 of 38 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Zanubrutinib | — | 32 | |||||
| Tislelizumab | — | — | — | 61 | |||
| Cisplatin | — | — | — | 15 | |||
| Carboplatin | — | — | — | 11 | |||
| Paclitaxel | — | — | — | 12 | |||
| Rituximab | — | — | — | — | 4 | ||
| Pamiparib | — | — | — | 8 | |||
| Obinutuzumab | — | — | — | 3 | |||
| Lenalidomide | — | — | — | — | 2 | ||
| Bendamustine | — | — | — | — | — | 1 | |
| Venetoclax | — | — | — | — | — | 1 | |
| Pemetrexed Disodium | — | — | — | — | — | 1 | |
| Placebos | — | — | — | — | — | 1 | |
| Gemcitabine Hydrochloride | — | — | — | — | — | 1 | |
| BGB-11417 | — | — | — | — | 4 | ||
| LBL-007 | — | — | — | — | — | 4 | |
| BGB-15025 | — | — | — | — | 3 | ||
| BGB-A445 | — | — | — | — | 3 | ||
| BGB-16673 | — | — | — | — | 3 | ||
| Pemetrexed | — | — | — | 6 | |||
| Capecitabine | — | — | — | 6 | |||
| 5-Fluorouracil | — | — | — | — | 3 | ||
| Nab paclitaxel | — | — | — | — | 3 | ||
| Sonrotoclax | — | — | — | — | 2 | ||
| BGB-A425 | — | — | — | — | — | 1 | |
| Azacitidine | — | — | — | — | — | 1 | |
| Posaconazole | — | — | — | — | — | 1 | |
| Bevacizumab or Bevacizumab biosimilar | — | — | — | — | — | 1 | |
| BGB-43395 | — | — | — | — | — | 3 | |
| Fulvestrant | — | — | — | — | — | 2 | |
| BGB-45035 | — | — | — | — | 2 | ||
| Tislelizumab IV | — | — | — | — | — | 1 | |
| Tislelizumab SC | — | — | — | — | — | 1 | |
| Histology-Based Chemotherapy Doublet | — | — | — | — | — | 1 | |
| BGB-53038 | — | — | — | — | — | 1 | |
| Cetuximab | — | — | — | — | — | 1 | |
| BG-68501 | — | — | — | — | — | 1 | |
| Letrozole | — | — | — | — | — | 1 |
Next readouts
- 2021-05-07
- 2023-08-21
- 2025-01-24
- 2025-05-23
- 2025-05-27
- 2025-06-17
- 2025-07-18
- 2025-07-31
- 2025-10-17
- 2025-12-01
Top conditions
- Healthy Volunteers11
- Advanced Solid Tumor8
- Marginal Zone Lymphoma6
- Advanced Solid Tumors6
- Non-small Cell Lung Cancer4
- Chronic Lymphocytic Leukemia4
- Mantle Cell Lymphoma4
- Non Small Cell Lung Cancer4
Frequently asked questions about BeiGene
- How many clinical trials does BeiGene have on ClinicalTrials.gov?
- BeiGene is listed as the lead sponsor on 135 clinical trials in ClinicalTrials.gov, 26 of which are currently active (recruiting, enrolling, or ongoing).
- How many of BeiGene's trials are in Phase 3?
- 23 of BeiGene's trials are in Phase 3, spread across 38 active drug programs.
- What therapeutic areas does BeiGene focus on?
- BeiGene's most-studied conditions on ClinicalTrials.gov are Healthy Volunteers, Advanced Solid Tumor, Marginal Zone Lymphoma, Advanced Solid Tumors, Non-small Cell Lung Cancer.
- When are BeiGene's next clinical trial readouts?
- BeiGene has 10 upcoming primary-completion readouts tracked here; the soonest is “A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL”, expected around 2021-05-07.